Michael D. Cameron

This paper describes a trimeric inhibitor, S22, that stabilizes the SARS-CoV-2 spike protein in a closed conformation, preventing ACE2 binding and viral entry.

This study identifies Dipyridamole as a drug that rescues mitochondrial dysfunction and neuronal death in ALS and AD iPSC-derived neurons by enhancing mitochondrial pyruvate uptake.

This paper designs an orally bioavailable small molecule that targets RNA to reduce 4R tau protein abundance and alleviate disease phenotypes in a mouse model.

This study investigates how ZIKV strain and dose affect fetal demise in Ifnar1-/- mice by analyzing interferon responses in maternal-fetal tissues.

This paper develops a selective non-muscle myosin II inhibitor, MT-228, with high brain penetration and efficacy in preclinical models, offering therapeutic potential for diseases like stimulant use disorder.

The paper shows that CRF2 receptor activation in the BLA during learning makes memory vulnerable to NMII inhibition, disrupting METH-associated memory but not COC-associated memory.

The paper characterizes two MOR PAMs that enhance opioid antinociception without increasing adverse effects in mouse models.